We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA approved Imfinzi (durvalumab) + BCG for high-risk non-muscle-invasive bladder cancer. 32% reduction in recurrence risk. Learn about the breakthrough in oncourology.
